| Project/Area Number |
26460952
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Keio University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
山本 博幸 聖マリアンナ医科大学, 医学部, 准教授 (40332910)
伊東 文生 聖マリアンナ医科大学, 医学部, 教授 (90223180)
渡邊 嘉行 聖マリアンナ医科大学, 医学部, 講師 (90329243)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2016: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2015: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2014: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | DNAメチル化 / 放射線化学療法 / 食道扁平上皮癌 / バイオマーカー / homologous recombination / 食道癌 / 食道がん |
|---|
| Outline of Final Research Achievements |
Chemoradiation therapy (CRT) is widely used for patients with esophageal squamous cell carcinoma (ESCC). Our aim was to identify methylated genes in tumor tissues by using genome wide DNA methylation analysis and to determine if DNA methylation status in tumor and adjacent nontumor tissues changes after CRT. Thirty-seven of 36,579 probes corresponding to the 15 unique genes were selected as candidate genes that are hypermethylated in ESCC. The most frequently selected probes (7 of 37) corresponded the CYP26C1 gene.CYP26C1 methylation levels were significantly higher in tumor than nontumor tissues in both test and validation set samples. Interestingly, methylation levels of CYP26C1 in tumor tissues were decreased in a subset of patients with ESCC after CRT. These results suggest that CYP26C1 methylation can be restored to the normal methylation levels by CRT in ESCC patients and that these epigenetic alterations can be used as molecular markers of cancer screening and treatment.
|
